News

2015

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Agios Pharmaceuticals 12.18.2015

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

Agios Pharmaceuticals 12.11.2015

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

Agios Pharmaceuticals 11.08.2015

Agios Reports Third Quarter 2015 Financial Results

Agios Pharmaceuticals 11.05.2015

Agios Outlines Key Clinical Development & Research Strategies

Agios Pharmaceuticals 10.16.2015

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

Agios Pharmaceuticals 08.06.2015

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Pharmaceuticals 06.24.2015

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Agios Pharmaceuticals 06.12.2015

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Pharmaceuticals 06.12.2015

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Pharmaceuticals 06.12.2015

Loading